Dr. Pascal Mensah | Ymmunoledge

Why We Can Trust GENOWME

Pascal MENSAH — Tue, 05 May 2026 09:18:32 +0000

Five arguments for trust in epigenetic testing — and the honest counterweight a careful clinician should carry alongside them

GENOWME (Genknowme SA, Lausanne) markets a Swiss epigenetic age and stress-load assay aimed at preventive medicine. Below are five reasons the test deserves clinical credibility, drawn from the company’s own technical documentation and cross-checked against the broader epigenetics literature. The honest counterweight at the end is not a disclaimer — it is the part of the argument that protects the rest from System 1 enthusiasm.

1. Methodological alignment with the field’s gold standard

Genknowme uses the Illumina Infinium MethylationEPIC array on whole-blood DNA after sodium-bisulfite conversion — the same platform behind virtually every major epigenetic clock of the last decade: Horvath, PhenoAge, GrimAge, DunedinPACE, and the methylation analyses in DIRECT-PLUS, DAMA, the Dunedin study, Generation Scotland, and Framingham. The chemistry is shared with academic labs worldwide: bisulfite converts unmethylated cytosines to uracil, leaving methylated cytosines intact, and the array hybridizes the converted DNA to roughly 850,000 CpG-targeted probes for fluorescent readout. This is not a proprietary black box. Whatever Genknowme measures can in principle be re-analyzed and cross- validated against the published literature.

2. Peer-reviewed validation of their proprietary signatures

Their allostatic-load signature is not asserted — it is published. Chamberlain et al. (2025), Bioscience Reports, “Development and validation of an epigenetic signature of allostatic load,” used a two-step process with replication in two independent research cohorts. Their lifestyle methylation signatures for tobacco and alcohol (Chamberlain et al., 2022, Clinical Epigenetics) and their COVID-severity work (2023, Swiss Medical Weekly) are also peer-reviewed. Peer review is not a guarantee of truth, but it is the threshold that separates “we believe” from “external reviewers have scrutinized the model and the data.”

3. Academic provenance and Swiss regulatory oversight

Genknowme is a spin-off of the University of Lausanne and Unisanté, founded by a physician and biologists. Their quality management system is authorized by the Swiss Federal Office of Public Health (OFSP/FOPH), meaning external regulatory inspection of every step in the workflow — extraction, bisulfite conversion, hybridization, scanning, and bioinformatics. This sits inside the Swiss data-protection regime, which guarantees anonymized sample handling and full patient ownership of DNA and results. Most direct-to-consumer “longevity” tests sold in less-regulated markets — particularly in the U.S. wellness space — do not have this governance layer. Regulation is not a substitute for science, but it raises the floor on operational reliability.

4. Population-specific calibration with conditional regression

The “horloge suisse” is calibrated on a Swiss reference population — the country with the highest life expectancy in Europe — using a conditional regression framework that explicitly incorporates lifestyle covariates (diet, alcohol, tobacco, physical activity). This is methodologically distinct from first-generation clocks (Horvath 2013) that were trained on pooled, lifestyle-blind cohorts. Conditioning on lifestyle is exactly what mathematically enables their sensitivity analysis: the ability to compare your declared exposure against the biological signature actually present in your DNA, and flag the discrepancy. That feature — telling whether reported lifestyle and biological reality match — only works if the clock is built this way. It also protects against the well-known weakness of first-generation clocks, which can be confounded by population structure when applied outside their training distribution.

5. Transparency of the gene panel and workflow

Genknowme publishes, in its patient-facing reports, the actual genes it reads. The 11 BioAge markers include ELOVL2, KLF14, AHRR, SLC7A11, FOXK1, JDP2, KCNQ4, PTPRN, IPO8, CALHM2, GPR62 and others — each with hundreds to thousands of aging- or lifestyle-related citations in the literature (ELOVL2 alone is one of the most-validated single-CpG age markers ever described). The 32 allostatic-load CpGs are also disclosed, distributed across the four physiological systems they claim to measure (metabolic, immune, cardiovascular, neuroendocrine). Their workflow is documented at the level of a four-day, roughly seventy-seven-step manual protocol with duplicate runs and a ten-step bioinformatics pipeline, processed in-house in Switzerland. Each marker can be cross-referenced against the literature. Many “biological age” services on the market do not disclose this much.

Trustworthy science is not science that asks to be believed. It is science that publishes its panel, opens its workflow, submits to regulation, and accepts that someone else can audit the result.

The honest counterweight

Five arguments for trust become more — not less — credible when paired with a clear-eyed view of where the trust limit lies. Three caveats are worth carrying alongside the case above:

Technical variance is real. Like every methylation-based clock, the absolute biological-age value is sensitive to white-blood-cell composition, sample handling, and batch effects. A test–retest difference of ±1 to 2 years can occur from technical noise alone. Single-point deltas should not be over-interpreted; longitudinal trends matter more than absolute numbers.
Independent prospective validation is more limited than for the reference clocks. GrimAge and DunedinPACE have decade-long follow-up cohorts (Generation Scotland, Dunedin, Framingham, Lothian Birth Cohorts) demonstrating prediction of mortality, T2D, CVD, dementia, and frailty. The Swiss clock’s predictive performance for these hard endpoints, in Genknowme’s own hands, is not yet published at the same scale. The technical foundation is sound, but the long-tail outcome data is still being built.
A sound test is not automatically a useful clinical decision. Methodological rigor at the laboratory bench does not, by itself, translate into better patient outcomes. The clinical value of an epigenetic- age measurement still depends on the physician’s framework — how the result is communicated, which interventions follow, and whether the patient is re-tested longitudinally to verify response. The test is a tool; the interpretation is medicine.

Read together, these caveats do not weaken the case for GENOWME — they sharpen it. They define what we can responsibly claim with a Swiss epigenetic clock today: a methodologically sound, regulatorily supervised, peer-reviewed-anchored, transparently constructed assay that is best used as part of a longitudinal preventive workflow under physician interpretation, with appropriate humility about absolute numbers.

Trust the method, calibrate the expectation, verify with re-measurement.

Selected references

Chamberlain JD et al. Development and validation of an epigenetic signature of allostatic load. Bioscience Reports. 2025.

Chamberlain JD et al. Blood DNA methylation signatures of lifestyle exposures: tobacco and alcohol consumption. Clinical Epigenetics. 2022.

Chamberlain JD et al. Epigenetic age and COVID-19 severity. Swiss Medical Weekly. 2023.

Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics. 2018;19:371–384.

Lu AT et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11:303–327.

Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.

Hillary RF et al. Epigenetic measures of ageing predict prevalence and incidence of leading causes of death and disease burden. Clinical Epigenetics. 2020;12:115.

Teschendorff AE et al. Epigenetic ageing clocks: statistical methods and emerging computational challenges. Nature Reviews Genetics. 2025.

McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Annals NY Acad Sci. 1998;840:33–44.

Emery O et al. Modifications épigénétiques et maladies cardiovasculaires : nouvel Eldorado. Revue Médicale Suisse. 2024.

The post Why We Can Trust GENOWME first appeared on Dr. Pascal Mensah | Ymmunoledge.

Your DNA Isn’t Your Destiny — Your Daily Choices Are

Pascal MENSAH — Tue, 05 May 2026 08:57:59 +0000

A rational case for understanding the epigenetic clock and its role in healthspan

You inherited your genes. You did not inherit your future. The same DNA you carry from birth to old age is read very differently depending on how you live. That reading layer — the chemical script that decides which genes are switched on or off — is called your epigenome. It is rewritten every day by what you eat, how you move, how you sleep, how you handle stress, and what you breathe. That is why identical twins, who share exactly the same genome, often age very differently. Same code; different choices; different biology.

A measurable trace of how you live

Modern science can now read this layer. By measuring tiny chemical marks (methylation) on your DNA, we estimate your biological age — how old your body actually behaves, regardless of the date on your passport. Hundreds of studies show that biological age predicts your future risk of heart disease, type 2 diabetes, cognitive decline and frailty more accurately than chronological age. It is, in effect, a forward-looking dashboard of your healthspan. GENOWME’s Swiss epigenetic clock measures eleven such markers, calibrated on the population with the highest life expectancy in Europe, plus a stress signature across your metabolic, immune, cardiovascular and neuroendocrine systems — capturing the cumulative wear of chronic stress.

Five levers that move the clock

Across randomized trials, the most effective interventions are also the most accessible:

Eat for your methylation. Mediterranean and plant-rich patterns; polyphenols (green tea, olive oil, berries); folate, B12, choline, omega-3 fatty acids; minimal ultra-processed food.
Move daily. Combined aerobic and strength training; reduce sedentary time. Even short walks lower epigenetic age acceleration.
Protect your sleep. Seven to nine hours, consistent timing, morning light exposure, no late-night meals.
Regulate stress. Meditation, breathwork, social connection. Chronic stress is biologically expensive — your epigenome records every bit of it.
Avoid the obvious toxins. Tobacco, excess alcohol, polluted air. Their epigenetic signatures are unmistakable, and so is their reversal once exposure stops.

Why this changes preventive care

Conventional medicine waits for symptoms. By the time blood pressure, blood sugar or cholesterol cross the line, your biology has been drifting for ten to twenty years. Epigenetic measurement detects that drift early — and, crucially, it can be re- measured. After three to twelve months of a targeted lifestyle protocol, you can see whether your biology actually moved. “I should eat better and exercise more” becomes “my biology shifted from fifty-two to forty-nine — and here is what worked.”

An honest word

The epigenetic clock is not a crystal ball. It is a high-resolution mirror. Lifestyle interventions typically slow aging or shift it back by one to three years; they do not rejuvenate you to a younger self. Different clocks measure different things, and small changes between measurements should not be over-interpreted. But across dozens of randomized trials, the direction is consistent: structured nutrition, movement, sleep and stress regulation move the clock the right way.

Your genes are the score. Your daily choices conduct the performance. The fixed code of your DNA was given to you — the way it is read is a daily decision, written one methyl group at a time.

GENOWME — Genknowme SA, Lausanne · Patient briefing · Sources: Horvath 2018, Belsky 2022 (DunedinPACE), Lu 2019 (GrimAge), Fitzgerald 2021, Yaskolka Meir 2023 (DIRECT-PLUS), Olaso-Gonzalez 2026.

The post Your DNA Isn’t Your Destiny — Your Daily Choices Are first appeared on Dr. Pascal Mensah | Ymmunoledge.

Epigenetics as a Preventive Tool for a Better Healthspan

Pascal MENSAH — Tue, 05 May 2026 08:37:15 +0000

A rational case for understanding epigenetic aging — for educated readers who want to understand, not be sold

Your DNA is not your destiny. Every cell in your body carries the same genome from birth to old age — about three billion base pairs, inherited at conception, that change very little over the course of your life. Yet identical twins, who share that genome, often diverge dramatically in how they age. One develops type 2 diabetes at fifty-five; the other runs marathons at seventy. The genetic code is identical. What differs is the way it is read.

That reading layer is the epigenome: a thin chemical script written on top of DNA that decides which genes are switched on, when, where, and how loudly. Food, exercise, sleep, sunlight, alcohol, tobacco, stress, pollution, social connection — all of these leave biochemical marks on your DNA. Those marks regulate inflammation, metabolism, immune function, and cellular repair. Over years, they accumulate into what we now call your biological age.

The fixed genome is read through a dynamic, modifiable layer — and that layer is open to intervention.

This is the central insight that makes epigenetics the most actionable tool in preventive medicine today: what you cannot change (your genes), the epigenome translates; what you can change (your lifestyle), the epigenome records and propagates. The aim of this paper is to lay out — without hype, and without minimizing what we genuinely know — the rational case for treating epigenetic measurement as a cornerstone of healthspan-oriented care.

1. The core biological principle

Genes provide the score; the epigenome conducts the performance. The genome is essentially fixed at conception. The epigenome is rewritten continuously, throughout life, by your environment and your choices. A useful image is the caterpillar and the butterfly: same DNA, two completely different organisms, because different gene programs are switched on at different stages. In humans, the same principle applies on a slower timescale. The genes you carry at twenty are the genes you carry at seventy; their expression patterns, however, will have shifted thousands of times in response to what you ate, how you slept, how you moved, whom you loved, and what you breathed.

This implies a re-framing of disease. With the exception of true monogenic disorders, most chronic diseases — cardiovascular disease, type 2 diabetes, neurodegeneration, many cancers — are not primarily genetic in origin. They are epigenetic and metabolic. Their roots lie in decades of accumulated cellular wear, written in methylation patterns and chromatin states long before any symptom appears. If we can read that wear, we can act on it before it becomes pathology.

2. Molecular mechanisms — how the epigenome writes, reads, and erases

Four mechanisms do the bulk of the epigenetic work:

DNA methylation. A methyl group (–CH3) is added to specific cytosine bases — mostly at sites called CpG dinucleotides — by enzymes called DNA methyltransferases (DNMTs), and removed by ten- eleven translocation (TET) enzymes. Methylation in a gene’s promoter typically silences the gene; loss of methylation reactivates it. The methyl groups themselves come from S-adenosylmethionine (SAM), which depends on B vitamins (folate B9, B12, B6), choline, and one-carbon metabolism. Your diet directly fuels — or starves — your methylation machinery.
Histone modifications. DNA is wrapped around protein spools called histones. Tags on histone tails — acetylation, methylation, phosphorylation — open or close chromatin, making genes accessible or hidden. The substrates again come from metabolism: acetyl-CoA from glucose and fatty-acid oxidation drives histone acetylation; α-ketoglutarate from the TCA cycle fuels histone demethylases.
The NAD+ / sirtuin axis. Sirtuins (SIRT1–7) are NAD+-dependent deacetylases. They erase acetyl marks on histones and other proteins, and they sit at the centre of mitochondrial biogenesis, DNA repair, circadian regulation, and stress response. NAD+ levels fall with age — by some estimates roughly half between forty and sixty — directly limiting sirtuin activity and accelerating epigenetic drift.
Non-coding RNAs. MicroRNAs and long non-coding RNAs add a fine-tuning layer on top of the others, modulating gene expression in response to environmental cues.

The epigenome is not abstract software. It is a chemical record written by metabolic substrates produced by your mitochondria.

SAM, acetyl-CoA, NAD+, α-ketoglutarate — these are the molecular currencies that translate lifestyle into gene expression. This is exactly why GENOWME’s gene panel makes biological sense. Markers like ELOVL2 (fatty-acid elongation, a canonical aging clock CpG), AHRR (xenobiotic response, a tobacco/pollution sentinel), KLF14 (metabolic regulation), JDP2 (transcriptional stress response), SLC7A11 (redox homeostasis), and FOXK1 (muscle development and repair) sit at the intersection of metabolism, immunity, and cellular stress — exactly where lifestyle leaves its strongest epigenetic footprints.

3. Systems-level interpretation — the epigenetic clock as an integrator

In the 2010s, Steve Horvath and others discovered that DNA methylation patterns at a few hundred CpG sites predict chronological age with extraordinary precision — typically within two to three years. These predictors became known as epigenetic clocks. A second generation (PhenoAge, GrimAge) and a third generation (DunedinPACE) moved beyond chronology: they predict mortality, cardiovascular disease, cancer, frailty, cognitive decline, and the onset of age-related disease — often outperforming traditional clinical risk factors.

These clocks are not magic. They integrate the cumulative biological footprint of several long-running processes: chronic low-grade inflammation (inflammaging), the gradual decline of immune competence (immunosenescence), mitochondrial dysfunction, circadian disruption, and the cumulative wear of chronic stress — what Bruce McEwen called allostatic load. GENOWME’s stress profile measures exactly this allostatic load with thirty-two DNA-methylation markers spread across four physiological systems: metabolic, immune, cardiovascular, and neuroendocrine.

The epigenetic clock is, in this sense, a molecular dashboard of your biology — a single readout that compresses thousands of subclinical processes into one number. A fifty-year-old with a biological age of forty-two is not just aging gracefully; she is, statistically, less likely to develop type 2 diabetes, hypertension, dementia, or coronary heart disease over the next decade than a peer with a biological age of fifty-eight. That is what makes the clock different from any classical biomarker: it is a forward-looking integrator, not a backward-looking symptom.

GENOWME’s specific contribution — the so-called “horloge suisse” (Swiss clock) calibrated on a Swiss reference population (the country with the highest life expectancy in Europe) — adds two practical layers. First, eleven epigenetic biomarkers selected for their lifestyle sensitivity. Second, a sensitivity analysis that compares your declared lifestyle (vegetables, activity, alcohol, tobacco) against the biological signature actually present in your DNA. That comparison is where the clinical insight lives.

4. A quantitative and thermodynamic perspective

A useful way to think about aging is in terms of information and entropy. The epigenome is, in part, an information storage system — methylation and chromatin patterns that tell each cell what to do. Over time, those patterns degrade. Methylation entropy increases: sites that should be tightly methylated drift toward partial methylation; sites that should be unmethylated drift the other way. The signal becomes noisier; the cell’s instructions become less clear.

Maintaining low-entropy epigenetic patterns is not free. Every methyl group transferred by a DNMT consumes one SAM (regenerated through ATP-dependent one-carbon metabolism). Every histone deacetylation by a sirtuin consumes one NAD+. Every chromatin remodeling event consumes ATP.
Maintaining youthful gene expression is, fundamentally, a thermodynamic battle against entropy — and that battle is fought by your mitochondria.

This explains a deep symmetry in the data. Mitochondrial dysfunction lowers NAD+ and acetyl-CoA → impairs sirtuin and chromatin function → drives epigenetic drift → accelerates biological aging. Conversely, caloric restriction, time-restricted eating, structured exercise, and quality sleep boost mitochondrial function → restore NAD+ → reactivate sirtuins → slow epigenetic aging. The same axis works in both directions, and the clock is sensitive enough to detect the swing.

The quantitative evidence has accumulated quickly:

An eight-week diet-and-lifestyle intervention reduced Horvath DNAmAge by approximately 3.2 years versus controls (Fitzgerald et al., 2021).
A twenty-four-month diet and physical-activity trial in postmenopausal women slowed GrimAge progression and reduced stochastic epigenetic mutations in cancer-related pathways (Fiorito et al., 2021, DAMA study).
An eighteen-month polyphenol-rich Mediterranean (“Green-MED”) diet attenuated multiple epigenetic clocks; participants showed roughly 8.9 months of favorable difference in biological age (Yaskolka Meir et al., 2023, DIRECT-PLUS).
A six-month multidomain intervention (nutrition + supervised exercise) in frail elders reduced PhenoAge and preserved methylation-based telomere length (Olaso-Gonzalez et al., 2026).
A very-low-calorie ketogenic diet decelerated biological age in obese patients across three independent clocks (Izquierdo et al., 2025).
Each one-standard-deviation increase in DunedinPACE predicts roughly 16% higher hypertension incidence (Kresovich et al., 2023) and 27% higher dementia risk (Belsky et al., 2022).
GrimAge predicts time-to-death, time-to-coronary heart disease, and time-to-cancer with effect sizes comparable to or stronger than classical risk factors (Lu et al., 2019; Hillary et al., 2020).

These numbers matter because they are not only associations. Several are randomized controlled trials, demonstrating bidirectional plasticity: the clock can speed up under stress and slow down under intervention, within months. That is the property that turns a biomarker into a clinical tool.

5. Clinical and translational implications

For preventive medicine, this changes the practice in three concrete ways.

5.1 — From symptoms to subclinical biology

Conventional medicine is reactive: it intervenes when symptoms or lab values cross a threshold (HbA1c above 6.5%, LDL above 190 mg/dL, blood pressure above 140/90). By that point the underlying biology has been deteriorating for ten to twenty years. Epigenetic aging measures detect that deterioration before any classical threshold is crossed. They move the diagnostic window upstream — from disease to biological readiness for disease.

5.2 — From population recommendations to personalized lifestyle dose-response

Public-health guidelines are uniform: five portions of vegetables a day, 150 minutes of activity a week, no more than two standard drinks. But people respond to those inputs very differently, and uniform advice cannot tell who is responding well. GENOWME’s sensitivity analysis captures exactly this. Someone who reports drinking three drinks a week but shows the methylation signature of seven is metabolically vulnerable and needs a tighter intervention. Someone who reports moderate exercise but shows the signature of an athlete is biologically protected. The same lifestyle input yields different epigenetic outputs — and only the epigenome reveals it.

5.3 — From single biomarkers to a longitudinal tracker

Because epigenetic patterns shift within weeks to months, the clock can be re-measured to monitor whether an intervention is working. This converts vague advice (“you should eat better”) into closed-loop biofeedback: did the last six months actually move your biology? For the patient, that is the difference between abstract guidance and a verifiable result. For the clinician, it is the difference between hope and evidence.

5.4 — The lifestyle levers that move the clock

The interventions with the strongest evidence for slowing epigenetic aging are, reassuringly, the ones with strong evidence for everything else:

Nutrition. Mediterranean and plant-rich patterns; polyphenols (green tea, olive oil, berries, herbs); adequate folate, B12, B6, and choline (the substrates of methylation); omega-3 fatty acids; minimal ultra-processed food and added sugar.
Movement. Combined aerobic and resistance training; reduction of sedentary time; even short bouts of light activity reduce epigenetic age acceleration.
Sleep and circadian alignment. Seven to nine hours, consistent timing, morning light exposure, restricted late-night eating. Circadian disruption shows up in epigenetic clocks within weeks.
Stress regulation. Meditation, breathwork, social connection, time in nature — strategies that reduce chronic allostatic load, which is exactly the variable GENOWME’s stress profile measures across metabolic, immune, cardiovascular, and neuroendocrine systems.
Avoidance of toxic exposures. Tobacco, excess alcohol, air pollution. The epigenetic signatures of these exposures are unambiguous and well validated.
Targeted micronutrients. Folate, B12, choline, magnesium, vitamin D — the substrates of methylation and chromatin chemistry. Deficiencies are common and easily corrected.

For a clinic, this defines a clean preventive workflow: measure epigenetic age and stress signature → map the lifestyle inputs → intervene for three to twelve months → re-measure → iterate. This is the operational meaning of “precision preventive medicine”.

6. A cognitive-bias check — what not to overclaim

Daniel Kahneman’s distinction between System 1 (fast, intuitive, emotionally compelling) and System 2 (slow, analytical, evidence-weighted) is worth applying to ourselves before we apply it to patients. The longevity field is uniquely vulnerable to System 1 reasoning: “biological age” sounds magical, photogenic, and instantly meaningful — it activates hope, vanity, and fear all at once, which is exactly the configuration
that produces bad decisions and bad science. So a few honest caveats:

Different clocks measure different things. Horvath’s first-generation clock tracks chronological age; GrimAge tracks mortality; DunedinPACE tracks pace of aging. They overlap but do not agree perfectly, and they capture related but distinct biology.
Reversibility has limits. Most lifestyle interventions slow the rate of aging or shift it back by one to three years; they do not “rejuvenate” you to a younger self. Cellular reprogramming is a research frontier, not a clinical reality.
Measurement variance matters. A clock value can shift by one to two years between measurements just from technical noise, blood-cell composition, or recent illness. Small changes should not be over-interpreted.
Causality is partial. Clocks correlate strongly with disease risk; they do not prove site-by-site causation. New causality-enriched clocks (DamAge, AdaptAge) are beginning to address this (Ying et al., 2023).
Lifestyle remains the lever. No supplement, peptide, or pharmacological “anti-aging” intervention has yet outperformed a structured combination of nutrition, exercise, sleep, and stress regulation in randomized trials.

The epigenetic clock is the best integrative biomarker we have for preventive medicine, and it is good enough to act on — provided we measure carefully, intervene with evidence, and track outcomes longitudinally. It is not a crystal ball. It is a high-resolution mirror.

7. Why this matters now

For most of the twentieth century, medicine waited for disease. The twenty-first century has the tools to act before disease. Genetics tells you your predispositions; the epigenome tells you how you are using them — and how to redirect them.

By measuring your epigenetic age and your stress signature today, then again in six months after a targeted lifestyle protocol, you convert “I should eat better and exercise more” into “my biology shifted from fifty-two to forty-nine — and here is what worked.” That is the closest thing modern medicine has to a longitudinal, modifiable, scientifically validated dashboard of your healthspan.

That is the rational case for placing epigenetic measurement at the centre of preventive care. It is mechanistically grounded. It is quantitatively measurable. It is biologically modifiable. It is clinically actionable. And, applied with discipline, it is honest about its limits.

The fixed code of your DNA was given to you. The way it is read is a daily decision — written one methyl group at a time.

Selected references

Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics. 2018;19:371–384.

Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303–327.

Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.

Fitzgerald KN, Hodges R, Hanes D, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging (Albany NY). 2021;13(7):9419–9432. Correction 2024.

Fiorito G, Caini S, Palli D, et al. DNA methylation-based biomarkers of aging were slowed down in a two-year diet and physical activity intervention trial: the DAMA study. Aging Cell. 2021;20(10):e13439.

Yaskolka Meir A, Keller M, Hoffmann A, et al. The effect of polyphenols on DNA methylation-assessed biological age attenuation: the DIRECT-PLUS randomized controlled trial. BMC Medicine. 2023;21:364.

Olaso-Gonzalez G, et al. A multidomain lifestyle intervention is associated with improved functional trajectories and favorable changes in epigenetic aging markers in frail older adults: a randomized controlled trial. Aging Cell. 2026.

Izquierdo AG, Crujeiras AB, et al. Epigenetic aging acceleration in obesity is slowed down by nutritional ketosis following very- low-calorie ketogenic diet (VLCKD). Nutrients. 2025.

Hillary RF, McCartney DL, Bermingham ML, et al. Epigenetic measures of ageing predict the prevalence and incidence of leading causes of death and disease burden. Clinical Epigenetics. 2020;12:115.

Kresovich JK, Park YM, Keller JA, et al. Methylation-based biological age and hypertension prevalence and incidence. Hypertension. 2023.

McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Annals of the New York Academy of Sciences. 1998;840:33–44.

Chamberlain JD, et al. Development and validation of an epigenetic signature of allostatic load. Bioscience Reports. 2025.

Galkin F, Kovalchuk O, Koldasbayeva D, Zhavoronkov A, Bischof E. Stress, diet, exercise: common environmental factors and their impact on epigenetic age. Ageing Research Reviews. 2023.

Pereira B, Correia FP, Alves IA, et al. Epigenetic reprogramming as a key to reverse ageing and increase longevity. Ageing Research Reviews. 2024.

Ying K, Liu H, Tarkhov AE, et al. Causality-enriched epigenetic age uncouples damage and adaptation. bioRxiv / Nature Aging. 2023.

Yamada H. Epigenetic clocks and EpiScore for preventive medicine: risk stratification and intervention models for age-related diseases. Journal of Clinical Medicine. 2025.

Topart C, Werner E, Arimondo PB. Wandering along the epigenetic timeline. Clinical Epigenetics. 2020;12:97.

Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019;18(6):e13028.

Kahneman D. Thinking, Fast and Slow. New York: Farrar, Straus and Giroux; 2011.

Drafted with reference to GENOWME (Genknowme SA, Lausanne) sample reports — BioAge & Lifestyle and Stress Overload — and to peer-reviewed primary literature retrieved via Consensus / Semantic Scholar in May 2026. The biological claims are sourced from randomized trials and reviews; the cognitive-bias caveats are the author’s own.

The post Epigenetics as a Preventive Tool for a Better Healthspan first appeared on Dr. Pascal Mensah | Ymmunoledge.

Find Your Solar-Aligned Eating Window

Pascal MENSAH — Mon, 04 May 2026 14:16:01 +0000

Eating Time — circadian eating window

Eating Time

Find the best time to eat with a circadian eating window aligned to the sun. Enter a location and a date.

Detecting your location…

—

Sunrise

—

Solar noon

—

Sunset

—

Moon

—

Eating Window

—

Breakfast

~35 g protein

3 eggs in EVOO; 150 g full-fat Greek yoghurt with chia, flax, lemon zest, EVOO; rocket + tomato + olives + ½ avocado; optional sourdough with tomato + olive oil. Coffee or green tea.

Last caffeine by —

Reset to suggestion

—

Lunch

largest meal · anchored on solar noon

180–220 g grilled white fish (dorada / rape) or lamb chops; 1 cup black rice or new potatoes — eat after the vegetables; large salad + grilled asparagus / artichoke / piquillo, EVOO + sherry vinegar; almonds or 30 g Mahón; sparkling water + lemon; optional 100 mL red wine with food. 10–15 min daylight walk immediately after.

Reset to suggestion

—

Optional snack

only if trained or genuinely hungry

Boiled egg + 20 g walnuts; Greek yoghurt + cinnamon; or 10 g 85 % chocolate with herbal tea. Skipping is preferred — it deepens autophagy.

Reset to suggestion

—

Dinner

light · low-GI · closes 2 h pre-sunset

Gazpacho or clear bone broth; 120–150 g oily fish (sardines / boquerones / salmon); steamed/roasted non-starchy veg with EVOO + garlic; ≈ ½ cup lentils or chickpeas; chamomile or lemon-balm tea. No simple sugars, no alcohol.

Reset to suggestion

—

Fasting window

water or unsweetened herbal tea

Overnight fast from end of dinner until tomorrow's break-fast.

Light Hygiene

Evening golden-hour walk—
Indoor < 50 lux from—
Blue-light cutoff—
< 10 lux from—
Lights-out—

The post Find Your Solar-Aligned Eating Window first appeared on Dr. Pascal Mensah | Ymmunoledge.

Proton Motive Force — The Chemiosmotic Engine of Life

Pascal MENSAH — Thu, 23 Apr 2026 09:41:59 +0000

About this course booklet

The proton motive force (Δp = ΔΨ_m − (2.303 RT/F)·ΔpH) is the central energetic currency of life. Generated by the electron transport chain, it captures a large fraction of the free energy released by NADH oxidation and redistributes it across ATP synthesis, transport processes, and signaling pathways.

Under physiological conditions (ΔΨ_m ≈ −150 to −180 mV, ΔpH ≈ 0.5–1), mitochondria convert redox energy into an electrochemical gradient of ~180–220 mV, corresponding to ~17–21 kJ/mol per proton.

This 13-page course booklet, authored in April 2026, provides a compact yet rigorous framework for understanding how Δp is generated, quantified, and perturbed in disease. It connects thermodynamic principles to real biological systems, with explicit numerical derivations and clinical implications.

Inside the booklet (5 modules)

Module 1 — What Is the Proton Motive Force?

Mitchell (1961): the immediate product of respiration is not a chemical intermediate but an electrochemical field across the IMM.
Δp has two additive components: electrical (ΔΨ_m) + voltage-equivalent chemical (ΔpH).
Healthy Δp ≈ 180–220 mV → ~19–21 kJ/mol per proton.

Module 2 — The Electrical Component (ΔΨ_m)

ETC is a vectorial charge pump. Matrix loses positive charge → electronegative (−150 to −180 mV, matrix-negative).
Stoichiometry table: Complex I = 4 H⁺, III = 4 H⁺, IV = 2 H⁺ per 2 e⁻ (Complex II = 0).
~75–80% of total pmf resides in ΔΨ_m in mammalian mitochondria.
Clinical: TMRM/JC-1 probes; metformin (Complex I), rotenone, oligomycin, FCCP; persistent depolarisation predicts mortality in sepsis.

Module 3 — The Chemical Component (ΔpH)

Matrix alkaline by 0.5–1 pH unit due to proton ejection + matrix buffering (phosphate, carboxylates, histidines).
ΔΨ_m and ΔpH are thermodynamically interconvertible: valinomycin collapses ΔΨ_m, nigericin collapses ΔpH, FCCP/CCCP/DNP collapse both.
Jagendorf’s acid-bath experiment (1966, chloroplasts) proved ATP synthesis can run on ΔpH alone.

Module 4 — Quantifying the PMF (Nernst Factor)

Full derivation: from Δμ̃_H+ = F·ΔΨ_m − 2.303 RT·ΔpH to the voltage form Δp = ΔΨ_m − (2.303 RT/F)·ΔpH.
At 37 °C: 2.303 RT/F ≈ 61.5 mV/pH unit.
Worked example: ΔΨ_m = −170 mV, ΔpH = 0.6 → Δp ≈ 207 mV → 20 kJ/mol H⁺ → 10 H⁺ × 20 = 200 kJ/mol captured per NADH → ~91 % of the 220 kJ/mol liberated by NADH → O2. At lower PMF (155–180 mV), the captured fraction drops to the textbook 150–175 kJ/mol (68–80 %) range.
ATP synthesis ceiling: ΔG_ATP ≤ ~4 H⁺ × 20 kJ = 80 kJ/mol ATP; measured ~55–60 kJ/mol (~70 % of max). The shortfall is the flux-driving dissipation required by the second law.

Module 5 — Integration, Physiology & Clinical Relevance

Δp governs: MCU-driven Ca²⁺ uptake, ROS production (reverse electron transport at Complex I), PINK1/Parkin mitophagy signalling, TIM23-dependent protein import.
Controlled uncoupling (UCP1–3, therapeutic uncouplers like BAM15) dissipates Δp as heat — feature, not bug.
Immunometabolic phenotypes correlate with Δp set-point: effector T cell / M1 macrophage = lowered, glycolytic, Warburg-like; memory / Treg = high ΔΨ_m, OXPHOS + FAO; senescent = low, unstable.
Pmf-collapse cascade: ETC injury → depolarisation → ATP synthase reversal → MPTP → cyt c release → DAMP-driven sterile inflammation (cGAS-STING, TLR9).
Therapeutic axes: NAD⁺ precursors (NMN, NR); cardiolipin stabilisation (SS-31/elamipretide); TPP⁺-targeted drugs (MitoQ, MitoTEMPO); mitochondrial transplantation.

Key equations

PMF (Mitchell): Δp = ΔΨ_m − (2.303 RT/F)·ΔpH
Energy per proton: ΔG = F·Δp ≈ 17–21 kJ/mol
Captured per NADH: 10 H⁺ × F·Δp ≈ 150–200 kJ/mol
Total redox drop NADH → O₂: ΔG°’ = −n·F·ΔE°’ = −2·96485·1.14 V ≈ −220 kJ/mol
Nernst factor (37 °C): 61.5 mV / pH unit
ATP synthesis ceiling: ΔG_ATP ≤ n·F·Δp ≈ 80 kJ/mol (measured −55 to −60 kJ/mol)

Who is this for?

PhD students in life sciences, biophysics, and bioenergetics
Medical doctors seeking a quantitative understanding of mitochondrial function
Researchers in redox biology and systems metabolism
Clinicians exploring immunometabolism and mitochondrial medicine

Key insight

The proton motive force is the universal electrochemical battery of life: generated by respiration, consumed by cellular work, and whose collapse is a quantitative signature of disease.

Note: The full PDF is in English.

Download the complete 13-page course booklet (PDF) – 10€

The post Proton Motive Force — The Chemiosmotic Engine of Life first appeared on Dr. Pascal Mensah | Ymmunoledge.

ΔΨm — The Two Faces of Mitochondrial Dysfunction

Pascal MENSAH — Wed, 22 Apr 2026 09:27:37 +0000

About this course booklet

The mitochondrial membrane potential (ΔΨm) is not a static number, but a dynamic balance between proton pumping by the electron transport chain and multiple discharge pathways including ATP synthesis, ion transport, and leak in mitochondrial dysfunction.

Under physiological conditions, ΔΨm is maintained around 150–180 mV, contributing to a total proton motive force (Δp) of ~180–220 mV. This electrochemical gradient captures a large fraction of the ~−220 kJ·mol⁻¹ released by NADH oxidation and powers ATP synthesis, metabolism, and signaling.

This 15-page course booklet provides a structured and clinically actionable framework to understand mitochondrial dysfunction as a bifurcation between two opposite states:

Hyperpolarisation (ΔΨm > 180 mV): ROS-driven, high-energy but unstable
Depolarisation (ΔΨm < 120 mV): energy failure, ATP deficit, collapse

Understanding this distinction is essential, as each state requires opposite therapeutic strategies.

Inside the booklet (4 chapters)

Chapter 1 — What creates and raises ΔΨm

Five levers, in order of quantitative weight:

Vectorial H⁺ pumping by Complexes I (4 H⁺), III (4 H⁺), IV (2 H⁺) per 2 e⁻ = 10 H⁺/NADH.
Substrate supply — TCA, β-oxidation, glutaminolysis, ketone bodies, malate–aspartate / glycerol-3-P shuttles.
Decreased discharge — low ADP / Pi, ANT or F_O inhibition → State 4 respiration → physiological hyperpolarisation.
Reduced leak — UCP down-regulation, cardiolipin integrity, tight cristae (MICOS/OPA1), supercomplex assembly.
Cation/H⁺ fine-tuning — K_ATP closure, Na⁺/H⁺ antiporter balance, physiological matrix Ca²⁺ activating PDH and 3 dehydrogenases.

Thermodynamic ceiling set by ΔG_phos ≈ −56 to −60 kJ·mol⁻¹ and n ≈ 2.7 H⁺/ATP → max sustainable Δp ≈ 200–230 mV. Healthy mitochondria hover at a “soft ceiling” ~180 mV because leak becomes non-ohmic above this.

Clinical hyperpolarised contexts: ischaemia–reperfusion (RET ROS burst), tumour cells (supranormal ΔΨm, mitocan-sensitive), early sepsis, effector T-cell priming.

Chapter 2 — What decreases ΔΨm

Five categories:

A. ETC inhibition — rotenone/MPP⁺/LHON (I), 3-NP/SDHx (II), antimycin A (III), CO/CN/NO-sepsis (IV), cyt c loss.
B. Substrate/cofactor deprivation — hypoxia, TCA stalls, β-oxidation failures (CPT-II, MCAD, VLCAD), CoQ₁₀ deficiency, Fe–S cluster defects (Friedreich).
C. Increased leak — DNP/FCCP, UCP1-3, fatty-acid cycling, ANT leak, cardiolipin peroxidation.
D. MPTP opening — Ca²⁺ overload + oxidative stress, cyclosporin-A-sensitive, catastrophic collapse.
E. ATP synthase reversal — IF₁-regulated; consumes glycolytic ATP to hold residual ΔΨm.

Feed-forward depolarisation loop: ΔΨm ↓ → PINK1/Parkin mitophagy, Ca²⁺ release, AMPK activation, ROS burst, cyt c release, deeper ΔΨm loss.
Clinical depolarised contexts: late sepsis (cytopathic hypoxia), heart failure, neurodegeneration, MELAS/LHON/Leigh, mitotoxic drugs (metformin, NRTIs, linezolid, valproate), NAFLD/NASH.
Immunometabolic consequence: macrophage lock into M1/HIF-1α; T-cell effector→memory transition fails; sepsis immunoparalysis.
Therapeutic hierarchy (5 tiers): remove insult → replenish substrates/cofactors → buffer redox → enhance mitophagy → experimental (elamipretide, NAD⁺ repletion, gene therapy).

Chapter 3 — Clinical distinction hyper- vs hypo-ΔΨm

Biochemical fingerprint (10 axes) — ETC flux, NADH/NAD⁺, CoQ redox, ROS, ATP/ADP, lactate, Ca²⁺ handling, PINK1/Parkin, morphology, heat output.

Four-step workup:

Clinical baseline — lactate, L/P ratio (>25 → Complex I/ETC block), β-OHB/AcAc, acylcarnitines.
Functional — Seahorse OCR, JC-1/TMRM imaging, muscle biopsy enzymology.
Genotype — mtDNA sequencing with heteroplasmy, nuclear panel, MR spectroscopy lactate peak.
Directional fingerprint — synthesis at bedside.

Rule of thumb:

High ROS + normal ATP + reperfusion context → hyperpolarised dysfunction.
High lactate + low ATP + AMPK on + mitophagy markers + chronic illness → depolarised dysfunction.

Therapeutic directionality (key insight): antioxidants and mild uncouplers protect hyperpolarised but harm depolarised; substrate/cofactor repletion and mitophagy enhancers rescue depolarised but not hyperpolarised; lipophilic cationic mitocans are selectively cytotoxic only to hyperpolarised tumour mitochondria (exp(FΔΨm/RT) accumulation law).

Chapter 4 — Integrative synthesis

ΔΨm × ROS × redox triangle phase-space map of bioenergetic states.
Bedside decision tree (5 Qs).
Memorisable quantitative anchors: resting ΔΨm 150–180 mV, Δp 180–220 mV, 2.303RT/F ≈ 61.5 mV/pH, stoichiometries, ΔG anchors, pathological thresholds.

Appendices

A. Key equations: Δp, ΔG° = −nFΔE°, ΔG_phos, Nernst accumulation, P/O ratio. Physical constants.
B. 16-entry glossary covering ΔΨm, Δp, ETC, RET, MPTP, ANT, MCU, UCP, PINK1/Parkin, cardiolipin, JC-1/TMRM, L/P ratio, β-OHB/AcAc, State 3/4, mitocan, IF₁.

Who is this for?

PhD students in bioenergetics and physiology
Medical doctors and clinicians
Researchers in metabolism and immunology
Professionals interested in mitochondrial medicine

Key insight

ΔΨm is not simply “high or low” — it defines two opposite pathological regimes, each requiring fundamentally different therapeutic strategies.

Note: The full PDF is in English.

Download the complete 15-page course booklet (PDF) – 5€

The post ΔΨm — The Two Faces of Mitochondrial Dysfunction first appeared on Dr. Pascal Mensah | Ymmunoledge.

Complex I — From Electron Free Energy to the First Proton Pump

Pascal MENSAH — Wed, 22 Apr 2026 09:27:37 +0000

About this course booklet

Complex I is the first and largest enzyme of the mitochondrial respiratory chain, where electron free energy is converted into proton translocation across the inner mitochondrial membrane (IMM).

The energy that moves a proton across the IMM is not chemical in the ATP sense — it is electron free energy, harvested from NADH as electrons flow down a redox gradient. The global driving force is the difference in midpoint potential between NADH/NAD⁺ (≈ −320 mV) and O₂/H₂O (+820 mV), corresponding to ΔG°’ ≈ −220 kJ·mol⁻¹ per 2 e⁻.

Complex I performs the first conversion step of this energy into the proton motive force (Δp), capturing part of this free energy while the remainder is dissipated as heat and entropy production.

This educational eBook (April 2026) is designed for PhD and MD students and provides a rigorous framework linking electron transfer, molecular mechanisms, and thermodynamics to the physical act of pumping protons.

About the booklet structure

This 10-page PDF is structured as a compact course:

Cover
Preface
Table of contents
2 core chapters
2 appendices (equations and glossary)

Core concepts developed in the booklet

Electron free energy as the driving force

ΔG°’ = −nFΔE°’ as the fundamental relation
NADH → O₂ releases ~−220 kJ·mol⁻¹
Complex I captures the first ~−70 kJ·mol⁻¹ step
Proton pumping as thermodynamically uphill work

Molecular mechanism — a redox-driven piston

L-shaped structure (~1 MDa, 45 subunits)
Redox arm: FMN + Fe–S clusters (N1a → N2)
Membrane arm: proton channels in ND1, ND2, ND4, ND5
Semiquinone (Q⁻•) as the mechanical trigger
HL helix as a long-range conformational transducer (~60 Å)

Electron transfer pathway:
NADH → FMN → Fe–S clusters → Q → QH₂

The redox drop does not directly bind protons — it triggers a conformational wave that drives proton translocation via alternating-access channels.

Stoichiometry and system behavior

1 NADH → 2 e⁻ → 4 H⁺ pumped
Total respiratory yield: 10 H⁺ per NADH
Reverse electron transport (RET) under high Δp
Complex I as a major ROS source in hyperpolarised states
AD transition regulating activity during ischemia

Quantitative and thermodynamic framework

ΔE (NADH → Q) ≈ +0.36 V
ΔG ≈ −70 kJ·mol⁻¹
Δp ≈ 180–220 mV
Work required: ~+77 kJ·mol⁻¹ for 4 H⁺
Efficiency ≈ 70–80%

Key relations:

ΔG°’ = −nFΔE°’
Δp = ΔΨ_m − (2.303 RT/F)·ΔpH

Complex I operates close to equilibrium but deliberately dissipates part of the energy to maintain forward flux — an expression of the second law of thermodynamics.

Clinical and translational relevance

Complex I deficiencies (Leigh syndrome, MELAS, LHON)
Ischemia-reperfusion injury and RET-driven ROS
Metformin as a reversible Complex I inhibitor
Hyperpolarisation vs depolarisation pathologies
Central role in mitochondrial dysfunction and energy failure

Key learning anchors

“The first proton is paid for by ~70 kJ·mol⁻¹ of electron free energy”
Semiquinone (Q⁻•) is a mechanical trigger, not an energy store
HL helix = long-range mechanical transducer
Efficiency < 100% = necessary entropy production

Who is this for?

PhD students in bioenergetics and molecular biology
Medical doctors interested in mitochondrial physiology
Researchers in redox biology
Clinicians exploring mitochondrial dysfunction

Key insight

Complex I is a redox-driven mechanical engine that converts electron free energy into proton pumping, initiating the proton motive force and cellular energy production.

Note: The full PDF is in English.

Download the complete 10-page course booklet (PDF) – 5€

The post Complex I — From Electron Free Energy to the First Proton Pump first appeared on Dr. Pascal Mensah | Ymmunoledge.

The M1/M2 Thermodynamic Axis: One Trade-Off Across Disease

Pascal MENSAH — Tue, 31 Mar 2026 15:46:58 +0000

The Core Biological Principle

Every macrophage makes a thermodynamic choice. It can run on Oxidative Phosphorylation (OXPHOS) — a high-efficiency, low-entropy metabolic state — or switch to aerobic glycolysis — a fast, wasteful, high-entropy mode. This thermodynamic axis determines whether the immune cell heals or damages the host.

This bioenergetic trade-off is not a side effect of disease. It is the molecular engine of disease. The same logic plays out identically across three clinically distinct conditions: sepsis, rheumatoid arthritis, and lung cancer.

The Bioenergetic Phenotype Comparison

Low entropy = order = health. High entropy = disorder = disease. Mitochondria are the cell’s entropy management system.

1. Sepsis — When the Engine Overheats

In sepsis, bacterial signals collapse the mitochondrial membrane potential (∆Ψm), flood the cell with reactive oxygen species (ROS), and force a metabolic switch from OXPHOS to glycolysis. The result is M1 macrophage hyperpolarisation: massive IL-1β, TNF-α, and IL-6 release — the cytokine storm. This is not just inflammation; it is thermodynamic failure. The cell dissipates energy as heat and entropy instead of extracting useful biological work.

Molecular Mechanisms

• ROS burst from Complex I/III → HIF-1α stabilisation → glycolytic gene upregulation
• Loss of ∆Ψm → impaired ATP synthase coupling → proton leak as heat
• mtDNA released into cytosol → cGAS-STING activation → amplified innate immune response
• Succinate accumulation → HIF-1α and IL-1β post-translational stabilisation

✓ Clinical Translation +
• NAD⁺ precursors (NMN, NR): restore Complex I cofactor availability, rescue OXPHOS capacity, and reduce M1 cytokine production in preclinical sepsis models.
• Mitochondria-targeted antioxidants (MitoQ, SS-31): scavenge IMM-generated superoxide, preserve ∆Ψm, and attenuate organ injury in CLP models.
• Biomarker opportunity: OCR/ECAR ratio (oxygen consumption vs. extracellular acidification) as a bedside metabolic index of macrophage inflammatory state.

2. Rheumatoid Arthritis — Entropy as a Chronic Tenant

The RA synovial joint is a permanently high-entropy microenvironment: hypoxic, glucose-depleted, acidic, and flooded with lactate. CD4⁺ T cells, macrophages, and fibroblast-like synoviocytes converge on aerobic glycolysis to survive. This metabolic shift is the inflammation — it sustains HIF-1α, fuels NF-κB, and keeps the NLRP3 inflammasome active. Meanwhile, Tregs (which depend on fatty acid oxidation and OXPHOS for their suppressive function) are metabolically starved in the same environment.

Molecular Mechanisms

• HIF-1α → GLUT1/LDHA upregulation → increased glycolytic flux → IL-17, IL-6 production
• Mitochondrial ROS → NF-κB and NLRP3 activation → sustained cytokine loop
• mTORC1 activation → suppresses OXPHOS → biases T cells away from Treg toward Th17 fate
• FAO-dependent Tregs: thermodynamic substrate starvation (low lipid availability in hypoxic joint) = loss of immune regulation

✓ Clinical Translation +
• Metformin: Complex I inhibitor → activates AMPK, restores metabolic balance, reduces glycolytic flux in RA immune cells. Anti-inflammatory effect independent of its glucose-lowering action.
• mTOR inhibitors (rapamycin analogues): shift T cell fate from Th17 toward Treg by derepressing OXPHOS and FAO.
• Biomarker opportunity: P/O ratio (ATP per O₂ consumed) and NAD⁺ /NADH in synovial immune cells as quantitative disease activity metrics.

3. Lung Cancer — The Tumor as a Thermodynamic Trap

Lung tumours export entropy into their microenvironment. They consume glucose ferociously via the Warburg effect, release lactate that acidifies the milieu, and deplete O₂ — creating a thermodynamic prison for tumour-infiltrating lymphocytes (TILs). TILs show declining oxygen consumption rates, reduced mitochondrial mass, and collapsed ∆Ψm. T cell exhaustion is not merely a transcriptional programme — it is a bioenergetic collapse. The tumour does not just hide from immunity. It starves it.

Molecular Mechanisms

• Warburg glycolysis in tumour cells → lactate efflux → TME acidification → T cell OXPHOS inhibition
• Glucose/glutamine depletion in TME → substrate-starved TILs → loss of effector ∆G
• Hypoxia → HIF-1α in tumour → VEGF/PD-L1 upregulation → immune exclusion and checkpoint exhaustion
• CD36^high TIL phenotype: excess lipid uptake → mitochondrial lipid overload → ferroptosis susceptibility

✓ Clinical Translation +
• Metabolic + checkpoint combination: OXPHOS enhancers (urolithin A, NMN) + anti-PD-1 show synergistic TIL reinvigoration in preclinical NSCLC models.
• Nutritional intervention: methionine restriction reduces Treg suppression; glutamine supplementation restores TIL respiratory capacity.
• Biomarker opportunity: Seahorse OCR profiling of TILs pre-therapy; hyperpolarised ¹³C-pyruvate MRI for real-time TME metabolic mapping.

Thermodynamic & Quantitative Perspective

Each disease represents a measurable deviation from thermodynamic efficiency. The key variables are not just molecular — they are quantifiable bioenergetic parameters that can be tracked clinically:

• ∆Ψm (mitochondrial membrane potential): Index of proton motive force and OXPHOS coupling. Collapse precedes immune dysfunction.

• P/O ratio (phosphorylation efficiency): ATP produced per O■ consumed. Declines with inflammatory reprogramming.

• OCR/ECAR ratio: Oxygen consumption vs. extracellular acidification rate — a real-time OXPHOS/glycolysis balance index.

• NAD⁺ /NADH ratio: Master redox sensor. Low NAD⁺ = impaired OXPHOS, increased entropy, impaired sirtuin-mediated immune regulation.

• mtDNA copy number / cytosolic mtDNA: Proxy for mitochondrial entropy accumulation and DAMP-mediated innate activation.

Unified Clinical Framework

Where This Is Going: Next-Generation Immune Biomarkers

The next generation of immune biomarkers will not be limited to cytokines alone. They will be metabolic:

• OCR/ECAR ratio in patient peripheral blood immune cells
• Mitochondrial membrane potential (∆Ψm) as an immune activation index
• NAD⁺ /NADH ratio as a systemic bioenergetic health score
• mtDNA release rate as a real-time entropy production marker
• Urinary lactate/pyruvate ratio as a non-invasive glycolytic shift readout

And the therapies that follow will not just block receptors — they will restore thermodynamic order to immune cells that have lost it. This is the promise of immunometabolism: not more immunosuppressants, but smarter bioenergetic strategies that give immune cells back what disease took from them.

When your patient’s immune system is failing, are you asking why it cannot fight — or only how to help it fight harder? The answer may be in the mitochondria.

Selected Evidence Base

1. Ji F et al. Crosstalk of mitochondrial dysfunction and macrophage polarization in sepsis. Front Immunol. 2026.
2. Xie R et al. Roles of immune cell metabolism in rheumatoid arthritis. Front Immunol. 2026.
3. Eivazzadeh Y et al. Immunometabolism in lung cancer. iScience. 2026.
4. Dwivedi V et al. Mitochondrial dysfunction and cellular senescence in ageing sarcopenia. Mol Biol Rep. 2026.
5. Seledtsov V. Mitochondria-targeted therapy in anti-aging medicine. J Biol Methods. 2026.
6. Glogowski PA et al. Reprogramming the mitochondrion in atherosclerosis. Antioxidants. 2025.
7. Xu Y et al. Nutritional intervention alleviates T cell exhaustion and empowers anti-tumor immunity. Front Immunol. 2026.
8. Zhang XY et al. The role of CD36 in immune function. Front Immunol. 2026.

This document is an evidence-based scientific communication intended for medical professionals, PhD researchers, and advanced students. All claims reflect peer-reviewed literature as of Q1 2026. Not intended as direct clinical guidance.

The post The M1/M2 Thermodynamic Axis: One Trade-Off Across Disease first appeared on Dr. Pascal Mensah | Ymmunoledge.

When Microglia Can’t Clean Up Their Mitochondria

Pascal MENSAH — Tue, 31 Mar 2026 15:46:58 +0000

The Mechanistic Chain

From mitochondrial damage and failed mitochondria clearance to locked neuroinflammation — step by step

1 Mitochondria Damaged

ATP↓ ROS↑ ΔΨm collapses

2 Lysosomes Fail

Mitophagy blocked Damaged organelles accumulate

3 mtDNA Escapes

Cytosolic release cGAS-STING + TLR9 fire

4 Inflammation Locked

Microglia → M1-like IL-1β, TNF-α, IFN-I

5 Loop Closes

Cytokines impair mitochondria further

Key insight: This is a positive feedback loop — not a linear cascade

STEPS 1–2

Mitochondria Fail. Lysosomes Can't Keep Up.

Mitophagy flux failure is the central bottleneck

ETC Dysfunction

Complexes I & III leak electrons → superoxide burst → membrane depolarisation (ΔΨm↓)

DRP1 Hyperfission

Damaged organelles fragment faster than the lysosomal clearing rate → net accumulation

Lysosomal Acidification Failure

Inflammatory cytokines impair V-ATPase → lysosomal pH rises → LC3-II cargo undegraded

NAD+ Depletion Loop

ROS activates PARP1 → NAD+ consumed → SIRT1/3 fall → PGC-1α drops → less biogenesis

STEPS 3–4 · mtDNA Escapes → Inflammation Locks In

Mitophagy
Blocked

Innate Sensors
Activate

Inflammation
Locked

Thermodynamic insight: Oxidised mtDNA (iron-driven ROS, Ferroptosis paper) is a stronger TLR9 agonist than native mtDNA — a redox-to-immune- signalling amplifier linking bioenergetic failure to locked inflammation.

Connection #1 — Mitochondria & Lysosomes in T Cell Immunometabolism

Same organelle crosstalk principle — different immune cell, same thermodynamic failure mode

same failure

Microglia (CNS)

Brain-resident innate immune cell
Requires OXPHOS-ATP for phagocytosis of synaptic debris
Mito-lysosome failure → mtDNA release → cGAS-STING
Locks into pro-inflammatory M1-like phenotype
Result: Neuroinflammation, depression-like behaviour

T Cells (Peripheral)

Adaptive immune cell in periphery + CNS
Lysosomal degradation required for TCR recycling & memory
Mito-lysosome failure → impaired autophagy → T cell exhaustion
Locks into dysfunctional exhausted phenotype (PD-1+ TIM-3+)
Result: Immunosuppression, failed anti-tumour / anti-viral immunity

Unifying principle: organelle quality control failure drives inflammatory fate — regardless of immune cell lineage

Connection #2 — Crosstalk of Mitochondrial Dysfunction & Macrophage Polarisation in Sepsis

Ji, Zhang et al. — Frontiers in Immunology | The peripheral macrophage analogue of microglial mitophagy failure

Microglia — Depression

Macrophage — Sepsis

Cell type

Microglia (CNS)

Macrophages (peripheral / liver / lung)

Trigger

Chronic stress, ROS accumulation

Infection, endotoxin (LPS)

Mito failure mode

Lysosomal acidification failure → mitophagy block

ETC uncoupling, ΔΨm loss, ROS burst

DAMP signalling

mtDNA via cGAS-STING / TLR9

mtROS, mtDNA via NLRP3, TLR9

Inflammatory output

IFN-I, IL-1β → neuroinflammation

IL-6, TNF-α → cytokine storm → immune paralysis

Resolution failure

Defective phagocytosis of synaptic debris

Impaired M2 polarisation, prolonged immunosuppression

Shared therapy

NAD+ precursors, mitophagy inducers

Mitochondrial antioxidants, substrate restoration, mitophagy

Connection #3 — IRG1–Itaconate Axis in Immunometabolism

The anti-inflammatory metabolite macrophages already produce — and a potential upstream regulator of organelle crosstalk

Inflammatory Stimulus

LPS / cytokines / ROS in macrophage

IRG1 → Itaconate Made

Aconitate decarboxylase in TCA: aconitate → itaconate; also blocks succinate dehydrogenase (Complex II)

Itaconate Alkylates KEAP1

Electrophilic itaconate modifies KEAP1 cysteines → Nrf2 freed and translocates to nucleus

Nrf2 Downstream Effects

↑ TFEB targets → lysosomal biogenesis & V-ATPase
↑ Mitophagy capacity (lysosomal pH restored)
↑ NQO1, HO-1, SOD antioxidant genes
↓ NLRP3 inflammasome activation

SDH Inhibition → Less mtROS

Itaconate competitively inhibits Complex II → reduces reverse electron transport → mitochondrial ROS drops → ΔΨm protected

Nrf2 → Lysosomal Rescue

TFEB co-activation restores lysosomal acidification (V-ATPase subunits) and biogenesis → unlocks mitophagosome-lysosome fusion → organelle crosstalk restored

The Upstream Hypothesis

If endogenous itaconate (or exogenous derivatives: 4-OI, DIMCI) restores mitochondria-lysosome crosstalk in microglia, metabolic reprogramming alone may break the neuroinflammation loop — without blocking cytokines downstream

Restoring Low Entropy

Therapeutic strategies targeting the organelle quality-control failure → inflammation axis

NAD+ Precursors

NR / NMN — restore SIRT1/3 activity, reactivate PGC-1α, rescue OXPHOS coupling and mitophagy flux

Mitophagy Inducers

Urolithin A, Rapamycin — directly stimulate PINK1/Parkin pathway; accelerate clearance of damaged organelles

Lysosomal Acidifiers

V-ATPase activators, TFEB inducers — restore lysosomal pH → unlock mitophagosome-lysosome fusion

cGAS-STING / TLR9 Block

H-151, C176 — interrupt downstream mtDNA sensing; reduce IFN-I and IL-1β without suppressing upstream quality control

Principle: The path to low entropy is through the organelle — not around it.

The post When Microglia Can’t Clean Up Their Mitochondria first appeared on Dr. Pascal Mensah | Ymmunoledge.

The Forgotten Layer of Your Exposome: Indoor Air Quality and Its Biological Consequences

Pascal MENSAH — Thu, 19 Mar 2026 17:21:38 +0000

The exposome — the totality of environmental exposures across a lifetime — was first formalised by Christopher Wild in 2005 as the necessary complement to the genome. It encompasses what we eat, the chemicals we absorb, the psychological stressors we endure, the microorganisms we encounter, and the air we breathe.¹ Indoor air quality therefore represents a major and continuous component of the exposome. It is, in essence, everything that is not your DNA but shapes how your DNA expresses itself.

Most discussions of the exposome focus on diet, exercise, and chronic stress. These are important. But there is a layer that is almost universally neglected in clinical practice — one that operates continuously, invisibly, and in the very space where people believe they are safe: indoor air.

"The air inside your home or clinic may be two to five times more polluted than the air outside. You cannot see it. Your patients are not measuring it. And its biological consequences are neither trivial nor short-term."

The Indoor Air Burden: What the Numbers Say

The United States Environmental Protection Agency has consistently found that indoor air pollutant concentrations can be two to five times higher than outdoor levels, and in some cases significantly more.² The World Health Organization estimates that indoor air pollution contributes to approximately 3.8 million premature deaths annually, primarily through cooking fuel exposure in low-income settings — but the relevant exposures in higher-income contexts are different in character, not in consequence.³

In homes and offices across Europe, the primary indoor air burden consists of:

PM2.5

Fine particulate matter — penetrates alveoli, enters circulation, reaches systemic organs

Source: combustion, candles, cooking, outdoor infiltration

VOCs

Volatile organic compounds — off-gassing from furniture, paint, cleaning products

Formaldehyde, benzene, toluene — many carcinogenic at chronic exposure

Nanoparticles

Ultra-fine particles <100nm — cross blood-brain barrier, trigger oxidative stress

Printers, cooking, candles, electronic devices

Bioaerosols

Mould spores, bacterial fragments, endotoxins — potent innate immune activators

HVAC systems, dampness, organic materials

NO₂

Nitrogen dioxide — gas stoves, impaired mucociliary clearance, heightened infection risk

Cooking, traffic infiltration, combustion appliances

Ions

Positive ion predominance in closed spaces — associated with fatigue, mood dysregulation

Electronic devices, HVAC systems, synthetic materials

The Biological Cascade: From Particle to Pathophysiology

Understanding why indoor air quality matters requires following the biological chain from inhalation to systemic consequence. This is not a linear process — it is a multi-system cascade that operates simultaneously across immunological, metabolic, and neuroendocrine pathways.

01 Inhalation & deposition

PM2.5 and nanoparticles deposit deep in alveolar tissue. Ultra-fine particles translocate directly to the bloodstream and reach the liver, spleen, and brain.

02 Innate immune activation

Alveolar macrophages detect particle-associated DAMPs and bioaerosol PAMPs via TLR4 and NLRP3 inflammasome, triggering IL-1β, IL-6, and TNF-α release.

03 Systemic inflammation

Cytokines enter circulation. CRP rises. Endothelial activation increases adhesion molecule expression. The inflammatory signal reaches tissues remote from the lung.

04 Mitochondrial stress

Particulates generate reactive oxygen species that impair mitochondrial electron transport chain function — depleting NAD⁺, disrupting membrane potential, and amplifying the inflammatory loop.

This cascade is not hypothetical. A growing body of epidemiological and mechanistic evidence links chronic indoor air pollutant exposure to accelerated cardiovascular ageing, increased incidence of metabolic syndrome, impaired cognitive function, and — of direct relevance to this platform — measurable shifts in immune cell composition and inflammatory tone.^4,5

Key study — particulate matter and immune dysregulation

A 2019 study published in Environmental Health Perspectives demonstrated that chronic exposure to PM2.5 at concentrations commonly found in urban indoor environments was associated with a significant shift in peripheral blood immune cell ratios — specifically, reduced natural killer cell cytotoxicity and elevated Th17/Treg ratios, consistent with a pro-inflammatory, immunosenescent phenotype.⁶

Crucially, these effects were observed at concentrations below current EU regulatory thresholds — suggesting that “compliant” air quality may still carry meaningful biological burden.

The Negative Ion Question: What the Evidence Actually Shows

Negative air ions — small, negatively charged oxygen molecules present in abundance near waterfalls, forests, and ocean coastlines — have been studied for decades in the context of respiratory and neurological health. The literature is heterogeneous, and clinical claims require careful evaluation. What can be stated with reasonable confidence is the following:

Air ionisation reduces airborne particulate burden. The mechanism is electrostatic: negative ions charge airborne particles, causing them to precipitate onto surfaces rather than remain suspended in breathing air. Multiple independent studies have confirmed particulate reduction efficacy, including the independent certification obtained by BIOW from ALCE Calidad S.L.⁷

The physiological effects of negative ion environments are biologically plausible. Serotonin metabolism, mucosal defence, and autonomic nervous system tone have all been proposed as downstream targets of ion environment. The evidence base is preliminary but consistent with a genuine environmental effect — not noise.⁸

Positive ion predominance in closed, electronics-rich spaces is measurable and common. The modern indoor environment — characterised by sealed windows, synthetic materials, HVAC recirculation, and dense electronics — systematically shifts ambient ion balance toward positive predominance. This is a physical fact of the contemporary indoor exposome, regardless of what we conclude about its therapeutic remediation.

The honest position is this: reducing your indoor particulate burden is clearly beneficial. The additional effects of negative ion enrichment are plausible and consistent with available evidence — but should not be overstated as established clinical outcomes.

Where This Fits in a Systems Biology Framework

From a thermodynamic and systems biology perspective, the indoor air argument is straightforward. Living systems — as dissipative structures — maintain biological organisation by continuously processing low-entropy inputs and exporting high-entropy waste. Every unnecessary environmental burden increases the metabolic cost of maintaining homeostasis.

A body breathing PM2.5-laden, positive-ion-predominant, VOC-contaminated air is allocating immune and metabolic resources to low-grade environmental defence that could otherwise support repair, regulation, and resilience. This is not a dramatic claim. It is a basic accounting of biological energy allocation.

Optimising your indoor air quality does not treat any disease. It reduces an unnecessary background burden on systems that are already managing substantial demands. In the framework of precision longevity medicine, this is precisely the kind of upstream, modifiable variable that deserves clinical attention.

A tool I personally use and have evaluated

BIOW — Air Purification for the Indoor Exposome

I evaluated BIOW over several months in both home and clinical office environments. My interest was specific: a device that addresses indoor particulate burden and ion balance without introducing ozone or secondary pollutants. What follows is my honest assessment — not a clinical endorsement.

Learn more about BIOW

Affiliate link — I receive a commission if you purchase through this link, at no extra cost to you. BIOW is not a medical device and does not treat, diagnose, or prevent any disease or condition. This is not medical advice.

Practical Considerations: What Actually Moves the Needle

If you are considering addressing your indoor air quality from a biological standpoint, the evidence supports a hierarchy of interventions. Air purification is one tool in a broader strategy:

Ventilation first. The single most effective intervention for most indoor environments is controlled ventilation — opening windows during low-pollution outdoor periods to dilute accumulated indoor contaminants. Free, accessible, and consistently underused.

Source reduction. Identify and remove or reduce sources of indoor contamination: gas stoves without adequate extraction, scented candles, synthetic cleaning products, off-gassing furniture in enclosed new spaces. The particle you do not generate does not need to be filtered.

Active filtration for residual burden. In urban environments, near-road locations, or spaces where ventilation is structurally limited, active filtration addresses the residual particle burden that ventilation alone cannot manage. This is the category where air purifiers like BIOW operate — and where the evidence base for benefit is strongest.

Monitor, don’t assume. Consumer-grade indoor air quality monitors (measuring PM2.5, VOCs, CO₂, and humidity) are now accurate and affordable. Measurement transforms indoor air quality from an abstract concern into an actionable data point. I recommend measuring before investing in any intervention.

Conclusion

The exposome framework asks us to account for the totality of environmental inputs that shape biological function. Indoor air — the medium through which we absorb roughly 15,000 litres of environmental signal every day — deserves a place in that accounting.

This is not about fear. It is about honest biological bookkeeping. Every unnecessary immune activation, every mitochondrial ROS cascade triggered by a preventable particulate exposure, every gram of NAD⁺ consumed in environmental defence rather than cellular repair — these are costs that compound over years and decades.

Addressing your indoor air quality will not substitute for sleep, nutrition, exercise, or stress management. But in a systems biology framework oriented toward long-term resilience, it is a legitimate and modifiable variable — and one that most clinicians and their patients are not yet measuring.

That seems worth changing.

References

Wild CP. Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1847–50.
US Environmental Protection Agency. Introduction to Indoor Air Quality. EPA 402-K-93-007. 2023.
World Health Organization. Household air pollution and health. Fact sheet. Geneva: WHO; 2023.
Bind MA, et al. Air pollution and markers of coagulation, inflammation, and endothelial function: associations and epigene–environment interactions in an elderly cohort. Epidemiology. 2012;23(2):332–40.
Chen R, et al. Ambient air pollution and daily mortality in Shanghai, China. Sci Rep. 2013;3:1–7.
Guo Q, et al. Fine particulate matter exposure and immune dysregulation: epidemiological and mechanistic evidence. Environ Health Perspect. 2019;127(9):097006.
ALCE Calidad S.L. Independent Certification Report: BIOW 100 Air Quality Performance. 2021.
Perez V, et al. Negative ions and mood states. A meta-analysis. PLOS ONE. 2013;8(1):e52609.

The post The Forgotten Layer of Your Exposome: Indoor Air Quality and Its Biological Consequences first appeared on Dr. Pascal Mensah | Ymmunoledge.